Pediatric Dermatology

Bernard A. Cohen, MD, shares what he thinks will be most exciting at this year's Society for Pediatric Dermatology Meeting in Indianapolis, Indiana.

Cynthia J. Trickett, PA-C, MPAS, discusses the personal and clinical effects of atopic dermatitis in adult and pediatric patients at the Maui Derm NP+PA 2022 Summer Conference in Colorado Springs, Colorado.

It is important for pediatric and family nurse practitioners caring for patients with dermatological conditions to be comfortable talking about the conditions with children, adolescents, and their parents.

From pediatric dermatology quizzes to the latest news in telederm to practical pearls on atopic dermatitis, alopecia, and vitiligo, there’s a lot going on at the SPD 2022 47th Annual Meeting, this year in Indianapolis, Indiana.

James Treat, MD, dives into pediatric patients dealing with alopecia areata, sleep issues in children with atopic dermatitis, and more.

Lisa Swanson, MD, sits down to discuss her recent presentation on pediatric dermatology featured at the 2022 SDPA Annual Summer Meeting held June 16-19, 2022, in Austin, Texas. She also describes her experience being the only pediatric dermatologist in Idaho.

Robert Dracker, MD, MHA, MBA, CPI, medical director of Summerwood Pediatrics & Infusacare Medical Services, sits down to discuss why choosing an infusion center with pediatric experience will improve treatment outcomes.

Robert Dracker, MD, MHA, MBA, CPI discussed considerations and developmentally appropriate interventions to promote high quality, patient-centered pediatric infusion care in a presentation at the 2022 National Infusion Center Association Annual Conference.

Pediatric patients taking 4 or more medications were more likely to experience medication errors.

In her presentation at the 3rd Annual Society of Dermatology Nurse Practitioners Symposium, Lisa Swanson, MD, discussed the important updates in pediatric dermatology, including early life interventions, food allergies, and more.

It's a hallmark of atopic dermatitis, but isn't always easy to assess. A presentation at the Revolutionizing Atopic Dermatitis meeting looks at available tools.

An abstract presented at the Revolutionizing Atopic Dermatitis conference discussed the impact of treatment with dupilumab on quality of life for children aged 6 months to 5 years with atopic dermatitis, as well as their caregivers.

In this video interview, we sit down with both Jennifer Lin Hsiao, MD, FAAD, and Scott Worswick, MD, FAAD, to talk in detail about their presentation, "Hidradenitis Suppurativa and Pityriasis Rubra Pilaris: Updates on Treatments for Two Conditions that are Difficult to Manage."

Determining the cause of a child's rash is important to proper diagnosis and management. Allergic contact dermatitis and eczema are 2 of most common causes.

In a presentation at the current AAD annual meeting, experts discussed differential diagnoses and clinical presentations in birthmarks and hamartomas.

Lawrence Eichenfield, MD, provides the newest updates in pediatric patient care, with a special update on COVID-19 skin symptoms in children.

Cantharidin 0.7% could be an emerging standard for molluscum treatment.

Ted Rosen, MD, and Sheila Fallon Friedlander, MD, discuss infectious disease updates at the virtual Maui Derm NP+PA Fall 2021 conference.

At Maui Derm NP+PA Fall 2021, Vikash S. Oza, MD, and Matthew J. Zirwas, MD, discuss the current Rx and Dx of atopic dermatitis in children.

According to a study in Annals of Dermatology and Venerology, pediatric patients with psoriasis in France frequently missed dermatologic consultations.

Some systemic medications may have increased risk for patients during the COVID-19 era, according to a recent Pediatric Dermatology Research Alliance (PeDRA) statement.

COVID-19’s lingering impact brings new considerations for treatment regimens for pediatric patients with psoriasis.

Many conditions are different in the pediatric population than in the adult population. How does hidradenitis suppurativa differ between the 2 groups?

A phase 3 trial studied the effectiveness of oral abrocitinib along with topical therapy for moderate-to-severe atopic dermatitis in teens.

In this episode, Alberto Pappo, MD, director, St. Jude Solid Tumor Division, discusses a registry he helped create aimed at helping physicians better understand pediatric melanoma called Molecular Analysis of Childhood MELanocytic Tumors (MACMEL).